课题基金 / 基金详情

Development of HRQOL Instruments for Children with CIs and their Parents

Development of HRQOL Instruments for Children with CIs and their Parents
为 CI 儿童及其家长开发 HRQOL 工具
批准号:
9247863
负责人:
Ivette Cejas
金额:
$16.08万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-04-01 至 2019-03-31

项目摘要

项目成果

Ivette Cejas的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
 DESCRIPTION (provided by applicant): Severe to profound hearing loss is associated with measurable deficits in health-related quality of life (HRQoL), reflecting its concomitant effects o language learning, social and emotional functioning, and academic performance. However, studies of cochlear implantation (CI) typically focus on clinical measures of efficacy related to communication development (e.g., auditory, speech, language skills), which does not represent the intervention's effects on daily functioning. HRQoL measures provide a crucial assessment of the impact of the condition and its treatment on physical, social and emotional functioning. To date, there are no CI-specific HRQoL measures for young children, adolescents and their parents (Morettin et al., 2013). The purpose of this study is to develop the first HRQoL instruments for pediatric cochlear implant recipients and their parents. We plan to complete the first two phases of instrument development for: 1) parents of children birth to five years, 2) school-age children 6-12, plus a parent-proxy measure and 3) adolescents with CIs ages 13-18. Instrument development will adhere to the FDA Guidance on patient-reported outcomes (FDA, 2009). Phase I consists of a synthesis and integration of existing literature and prior HRQoL instruments for this population and data collection at national CI Centers to ensure geographic and racial/ethnic diversity, and includes: 1) an integration of prior literature and instruments to form a testable conceptual framework, 2) focus groups with stakeholders (surgeons, audiologists, speech pathologists), 3) open-ended interviews with parents of children birth to 18 years, children ages 6 to 18 years, and 4) cognitive testing of the 4 draft instruments. Eight one-hour focus groups will be conducted with stakeholders, such as CI surgeons, pediatric audiologists, auditory verbal therapists, and community providers. Next, open-ended interviews will be conducted and audiotaped with 110 parents and children to identify the effects of both deafness and CI use on several areas of functioning. All focus groups and open-ended interviews will be transcribed and content-analyzed to identify key themes and quantify the frequency of their endorsement. Items will then be generated based on saturation matrices of specific content, resulting in draft versions of all four QOL-CI measures. Lastly, cognitive interviews, using standardized "think aloud" procedures, will be performed with 96 parents and CI users (ages 6 to 18). Cognitive interviewing techniques are now widely used to gain information from respondents about the clarity and comprehensiveness of the items and response scales. Completion of this project will yield the final draft instruments to be field-testd in a national, psychometric validation study to assess reliability, validity, and responsivity to change. Instruments will be developed using an electronic format to enhance their utility and interpretability. These instruments will facilitate evaluation of the effectiveness of CI's over tie, provide patient-centered outcome measures for other interventions (e.g., auditory-verbal therapy, behavioral interventions), and provide information at the patient/family level for targete interventions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of HRQOL Instruments for Children with CIs and their Parents
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: